Symptomatic relief from treatment-induced psychosis in Parkinson's disease: An open-label pilot study with remoxipride

2004 ◽  
Vol 9 (2) ◽  
pp. 197-200 ◽  
Author(s):  
Tilak Mendis ◽  
Erich Mohr ◽  
Amanda George ◽  
Ilene N. Rusk ◽  
Peggy Gray ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Symptomatic Relief ◽  
Open Label

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

2006 ◽  
Vol 21 (12) ◽  
pp. 2078-2081 ◽  
Author(s):  
Joseph H. Friedman ◽  
Robert M. Berman ◽  
Christopher G. Goetz ◽  
Stewart A. Factor ◽  
William G. Ondo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Open Label ◽  
Flexible Dose

CQP 201-403 in Parkinson's disease: An open-label pilot study

1989 ◽  
Vol 4 (3) ◽  
pp. 278-281 ◽  
Author(s):  
Ronald F. Pfeiffer ◽  
Leonel H. Herrera ◽  
Carolyn S. Glaeske ◽  
Ruth E. Hofman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Open Label

scholarly journals Rotigotine Objectively Improves Sleep in Parkinson’s Disease: An Open-Label Pilot Study with Actigraphic Recording

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Giovanna Calandra-Buonaura ◽  
Pietro Guaraldi ◽  
Andrea Doria ◽  
Stefano Zanigni ◽  
Stefania Nassetti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Motor Activity ◽  
Sleep Quality ◽  
Sleep Disturbances ◽  
Open Label ◽  
Sleep Complaints ◽  
Objective Evidence ◽  
Rotigotine Treatment

Sleep disturbances represent important predictors of poor quality of life (QoL) in Parkinson’s disease (PD). This open-label pilot study aimed to objectively assess, by means of actigraphic recording, effect of rotigotine on sleep in PD patients with self-reported sleep complaints. 15 PD patients underwent one-week actigraphic recording before (T0) and during (T1) rotigotine treatment, which was titrated to the dose subjectively improving motor symptoms (4–8 mg/24 h). Sleep disturbances, daytime sleepiness, cognitive performance, QoL, and depression were also evaluated with questionnaires. Actigraphic recordings showed a significant reduction in nocturnal motor activity and mean duration of wake episodes after sleep onset during rotigotine treatment compared to baseline. In 10 patients presenting objective evidence of poor sleep quality at T0 (sleep efficiency ≤ 85%), rotigotine also significantly improved other sleep parameters and further reduced nocturnal motor activity and mean duration of wake episodes. A significant decrease in number and duration of daytime sleep episodes was also observed at T1. Finally we confirmed that rotigotine significantly improves perceived sleep quality and QoL. Our study showed for the first time that rotigotine is associated with an objective improvement of nocturnal and diurnal sleep disturbances in PD patients with self-reported sleep complaints. This study is registered with AIFA-observational study registry number 12021.

scholarly journals Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open‐Label Pilot Study

2019 ◽  
Vol 12 (6) ◽  
pp. 586-590
Author(s):  
Alexander Khlebtovsky ◽  
Israel Steiner ◽  
Therese Treves ◽  
Ruth Djaldetti
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Open Label

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease

2005 ◽  
Vol 20 (9) ◽  
pp. 1205-1209 ◽  
Author(s):  
Theresa A. Zesiewicz ◽  
Kelly L. Sullivan ◽  
John L. Maldonado ◽  
William O. Tatum ◽  
Robert A. Hauser
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Open Label
Sign in / Sign up

Export Citation Format

Share Document